GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00305165 | Lung | IAC | regulation of axon extension | 19/2061 | 95/18723 | 7.04e-03 | 4.83e-02 | 19 |
GO:002260413 | Lung | AIS | regulation of cell morphogenesis | 65/1849 | 309/18723 | 2.97e-09 | 5.09e-07 | 65 |
GO:006056012 | Lung | AIS | developmental growth involved in morphogenesis | 51/1849 | 234/18723 | 4.43e-08 | 5.24e-06 | 51 |
GO:003109813 | Lung | AIS | stress-activated protein kinase signaling cascade | 51/1849 | 247/18723 | 2.69e-07 | 2.37e-05 | 51 |
GO:001604912 | Lung | AIS | cell growth | 83/1849 | 482/18723 | 3.26e-07 | 2.79e-05 | 83 |
GO:001810512 | Lung | AIS | peptidyl-serine phosphorylation | 60/1849 | 315/18723 | 4.75e-07 | 3.64e-05 | 60 |
GO:000725413 | Lung | AIS | JNK cascade | 38/1849 | 167/18723 | 7.27e-07 | 5.36e-05 | 38 |
GO:005140313 | Lung | AIS | stress-activated MAPK cascade | 48/1849 | 239/18723 | 1.38e-06 | 8.75e-05 | 48 |
GO:199013812 | Lung | AIS | neuron projection extension | 38/1849 | 172/18723 | 1.57e-06 | 9.85e-05 | 38 |
GO:004858812 | Lung | AIS | developmental cell growth | 47/1849 | 234/18723 | 1.77e-06 | 1.05e-04 | 47 |
GO:001820912 | Lung | AIS | peptidyl-serine modification | 61/1849 | 338/18723 | 2.49e-06 | 1.41e-04 | 61 |
GO:003367412 | Lung | AIS | positive regulation of kinase activity | 77/1849 | 467/18723 | 4.67e-06 | 2.31e-04 | 77 |
GO:004867512 | Lung | AIS | axon extension | 28/1849 | 120/18723 | 1.22e-05 | 4.71e-04 | 28 |
GO:004586012 | Lung | AIS | positive regulation of protein kinase activity | 65/1849 | 386/18723 | 1.27e-05 | 4.78e-04 | 65 |
GO:007190012 | Lung | AIS | regulation of protein serine/threonine kinase activity | 61/1849 | 359/18723 | 1.76e-05 | 6.17e-04 | 61 |
GO:007190211 | Lung | AIS | positive regulation of protein serine/threonine kinase activity | 38/1849 | 200/18723 | 6.00e-05 | 1.65e-03 | 38 |
GO:004863811 | Lung | AIS | regulation of developmental growth | 55/1849 | 330/18723 | 7.63e-05 | 1.95e-03 | 55 |
GO:004863911 | Lung | AIS | positive regulation of developmental growth | 34/1849 | 174/18723 | 8.08e-05 | 2.02e-03 | 34 |
GO:001097512 | Lung | AIS | regulation of neuron projection development | 69/1849 | 445/18723 | 1.05e-04 | 2.53e-03 | 69 |
GO:004577312 | Lung | AIS | positive regulation of axon extension | 13/1849 | 42/18723 | 1.34e-04 | 2.97e-03 | 13 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0453026 | Endometrium | AEH | Tight junction | 54/1197 | 169/8465 | 1.99e-09 | 3.80e-08 | 2.78e-08 | 54 |
hsa0412016 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
hsa0472216 | Endometrium | AEH | Neurotrophin signaling pathway | 31/1197 | 119/8465 | 4.07e-04 | 3.07e-03 | 2.25e-03 | 31 |
hsa0516626 | Endometrium | AEH | Human T-cell leukemia virus 1 infection | 50/1197 | 222/8465 | 4.30e-04 | 3.11e-03 | 2.27e-03 | 50 |
hsa04530112 | Endometrium | AEH | Tight junction | 54/1197 | 169/8465 | 1.99e-09 | 3.80e-08 | 2.78e-08 | 54 |
hsa0412017 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
hsa0472217 | Endometrium | AEH | Neurotrophin signaling pathway | 31/1197 | 119/8465 | 4.07e-04 | 3.07e-03 | 2.25e-03 | 31 |
hsa05166111 | Endometrium | AEH | Human T-cell leukemia virus 1 infection | 50/1197 | 222/8465 | 4.30e-04 | 3.11e-03 | 2.27e-03 | 50 |
hsa0453027 | Endometrium | EEC | Tight junction | 54/1237 | 169/8465 | 6.56e-09 | 1.27e-07 | 9.46e-08 | 54 |
hsa0412023 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
hsa0516627 | Endometrium | EEC | Human T-cell leukemia virus 1 infection | 52/1237 | 222/8465 | 2.73e-04 | 2.36e-03 | 1.76e-03 | 52 |
hsa0472222 | Endometrium | EEC | Neurotrophin signaling pathway | 30/1237 | 119/8465 | 1.54e-03 | 9.55e-03 | 7.12e-03 | 30 |
hsa0453036 | Endometrium | EEC | Tight junction | 54/1237 | 169/8465 | 6.56e-09 | 1.27e-07 | 9.46e-08 | 54 |
hsa0412033 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
hsa0516636 | Endometrium | EEC | Human T-cell leukemia virus 1 infection | 52/1237 | 222/8465 | 2.73e-04 | 2.36e-03 | 1.76e-03 | 52 |
hsa0472232 | Endometrium | EEC | Neurotrophin signaling pathway | 30/1237 | 119/8465 | 1.54e-03 | 9.55e-03 | 7.12e-03 | 30 |
hsa0412018 | Prostate | BPH | Ubiquitin mediated proteolysis | 61/1718 | 142/8465 | 5.50e-10 | 9.07e-09 | 5.61e-09 | 61 |
hsa0453028 | Prostate | BPH | Tight junction | 68/1718 | 169/8465 | 1.70e-09 | 2.55e-08 | 1.58e-08 | 68 |
hsa0516628 | Prostate | BPH | Human T-cell leukemia virus 1 infection | 79/1718 | 222/8465 | 6.00e-08 | 6.83e-07 | 4.23e-07 | 79 |
hsa0401010 | Prostate | BPH | MAPK signaling pathway | 87/1718 | 302/8465 | 2.05e-04 | 1.13e-03 | 6.98e-04 | 87 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAP3K1 | SNV | Missense_Mutation | | c.4121A>G | p.Asn1374Ser | p.N1374S | Q13233 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A2-A04N-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
MAP3K1 | SNV | Missense_Mutation | | c.4310G>T | p.Cys1437Phe | p.C1437F | Q13233 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A04N-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
MAP3K1 | SNV | Missense_Mutation | | c.3989N>G | p.Ser1330Trp | p.S1330W | Q13233 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A0EU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAP3K1 | SNV | Missense_Mutation | | c.3517N>G | p.His1173Asp | p.H1173D | Q13233 | protein_coding | tolerated_low_confidence(0.12) | benign(0.395) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
MAP3K1 | SNV | Missense_Mutation | | c.2305C>T | p.Pro769Ser | p.P769S | Q13233 | protein_coding | tolerated(0.06) | benign(0.158) | TCGA-A2-A1G1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAP3K1 | SNV | Missense_Mutation | | c.4298N>C | p.Trp1433Ser | p.W1433S | Q13233 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A259-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
MAP3K1 | SNV | Missense_Mutation | | c.3934N>T | p.Ala1312Ser | p.A1312S | Q13233 | protein_coding | tolerated(0.06) | possibly_damaging(0.533) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
MAP3K1 | SNV | Missense_Mutation | novel | c.975N>A | p.Asn325Lys | p.N325K | Q13233 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
MAP3K1 | SNV | Missense_Mutation | novel | c.3373N>G | p.Asn1125Asp | p.N1125D | Q13233 | protein_coding | deleterious_low_confidence(0.01) | benign(0.03) | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | | SD |
MAP3K1 | SNV | Missense_Mutation | rs755757854 | c.1403N>C | p.His468Pro | p.H468P | Q13233 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | cisplatin | CISPLATIN | 21636554 |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | gefitinib | GEFITINIB | 21636554 |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | paclitaxel | PACLITAXEL | 21636554 |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 223366167 | E-6201 | |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | docetaxel | DOCETAXEL | 21636554 |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | erlotinib | ERLOTINIB | 21636554 |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | CHEMBL1097999 | E-6201 | |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | carboplatin | CARBOPLATIN | 21636554 |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | CI-1040 | CI-1040 | |
4214 | MAP3K1 | CLINICALLY ACTIONABLE, ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | Tumor necrosis factor alpha (TNF-alpha) inhibitors | | 27670765 |